
Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually

The study demonstrated strong clinical accuracy in differentiating pancreatic cancer patients from control subjects

The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

The disease is the fourth leading cause of cancer-related death in the US, accounting for 3.3% of new cancer cases

Pancreatic cancer accounts for approximately 3.3% of all new cancer cases

More than 90% of patients with locally advanced disease are not eligible for surgery

Study reveals new findings of dietary changes within pancreatic cancer cells

Pancreatic cancer is the third leading cause of cancer-related deaths, with over 430,000 deaths each year

The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation

Inspection of third-party manufacturing plant delayed due to COVID-19

Sales of immunotherapy Opdivo decreased due to COVID-19 impact